Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 244

1.

Clinical significance of plasma fibrinogen level as a predictive marker for postoperative recurrence of esophageal squamous cell carcinoma in patients receiving neoadjuvant treatment.

Matsuda S, Takeuchi H, Fukuda K, Nakamura R, Takahashi T, Wada N, Kawakubo H, Saikawa Y, Omori T, Kitagawa Y.

Dis Esophagus. 2014 Sep-Oct;27(7):654-61. doi: 10.1111/dote.12115. Epub 2013 Aug 27.

PMID:
23980622
2.

Cumulative prognostic scores based on plasma fibrinogen and serum albumin levels in esophageal cancer patients treated with transthoracic esophagectomy: comparison with the Glasgow prognostic score.

Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Takahashi T, Wada N, Saikawa Y, Omori T, Kitagawa Y.

Ann Surg Oncol. 2015 Jan;22(1):302-10. doi: 10.1245/s10434-014-3857-5. Epub 2014 Jun 21.

PMID:
24952029
3.

Pretreatment T3-4 stage is an adverse prognostic factor in patients with esophageal squamous cell carcinoma who achieve pathological complete response following preoperative chemoradiotherapy.

Chao YK, Chan SC, Liu YH, Chen HW, Wan YL, Chang HK, Fan KH, Liu HP.

Ann Surg. 2009 Mar;249(3):392-6. doi: 10.1097/SLA.0b013e3181949e9f.

PMID:
19247024
5.

Plasma fibrinogen levels are correlated with postoperative distant metastasis and prognosis in esophageal squamous cell carcinoma.

Zhang D, Zhou X, Bao W, Chen Y, Cheng L, Qiu G, Sheng L, Ji Y, Du X.

Oncotarget. 2015 Nov 10;6(35):38410-20. doi: 10.18632/oncotarget.4800.

6.

Long-term outcomes following neoadjuvant chemoradiotherapy in patients with clinical T2N0 esophageal squamous cell carcinoma.

Chen WH, Chao YK, Chang HK, Tseng CK, Wu YC, Liu YH, Hsieh MJ, Liu HP.

Dis Esophagus. 2012 Apr;25(3):250-5. doi: 10.1111/j.1442-2050.2011.01243.x. Epub 2011 Sep 23.

PMID:
21951719
7.

Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.

Yoshida N, Baba Y, Shigaki H, Harada K, Iwatsuki M, Sakamoto Y, Miyamoto Y, Kurashige J, Kosumi K, Tokunaga R, Watanabe M, Baba H.

Int J Clin Oncol. 2016 Dec;21(6):1071-1078. Epub 2016 Jun 2.

PMID:
27255393
8.

Serum soluble E-cadherin is a potential prognostic marker in esophageal squamous cell carcinoma.

Chung Y, Law S, Kwong DL, Luk JM.

Dis Esophagus. 2011 Jan;24(1):49-55. doi: 10.1111/j.1442-2050.2010.01093.x. Epub 2010 Aug 30.

PMID:
20807231
9.

Postoperative Adjuvant Therapy Improves Survival in Pathologic Nonresponders After Neoadjuvant Chemoradiation for Esophageal Squamous Cell Carcinoma: A Propensity-Matched Analysis.

Hsu HY, Chao YK, Hsieh CH, Wen YW, Chang HK, Tseng CK, Liu YH.

Ann Thorac Surg. 2016 Nov;102(5):1687-1693. doi: 10.1016/j.athoracsur.2016.05.026. Epub 2016 Jul 22.

PMID:
27457831
10.

REG1A expression status suggests chemosensitivity among advanced thoracic esophageal squamous cell carcinoma patients treated with esophagectomy followed by adjuvant chemotherapy.

Sato Y, Motoyama S, Nanjo H, Ito S, Yoshino K, Sasaki T, Kuribayashi K, Nagaki Y, Imai K, Saito H, Minamiya Y, Ogawa J.

Ann Surg Oncol. 2013 Sep;20(9):3044-51. doi: 10.1245/s10434-013-2983-9. Epub 2013 May 5.

PMID:
23645481
11.

Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma.

Kijima T, Arigami T, Uchikado Y, Uenosono Y, Kita Y, Owaki T, Mori S, Kurahara H, Kijima Y, Okumura H, Maemura K, Ishigami S, Natsugoe S.

Cancer Sci. 2017 Feb;108(2):193-199. doi: 10.1111/cas.13127.

12.

Circulating Cell-Free DNA Levels Could Predict Oncological Outcomes of Patients Undergoing Esophagectomy for Esophageal Squamous Cell Carcinoma.

Hsieh CC, Hsu HS, Chang SC, Chen YJ.

Int J Mol Sci. 2016 Dec 17;17(12). pii: E2131. doi: 10.3390/ijms17122131.

13.

Trimodality therapy of esophagectomy plus neoadjuvant chemoradiotherapy improves the survival of clinical stage II/III esophageal squamous cell carcinoma patients.

Fujiwara Y, Yoshikawa R, Kamikonya N, Nakayama T, Kitani K, Tsujie M, Yukawa M, Inoue M, Yamamura T.

Oncol Rep. 2012 Aug;28(2):446-52. doi: 10.3892/or.2012.1847. Epub 2012 Jun 1.

14.

High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.

Cheng JC, Graber MS, Hsu FM, Tsai CL, Castaneda L, Lee JM, Chang DT, Koong AC.

Ann Surg Oncol. 2014 Jul;21(7):2361-8. doi: 10.1245/s10434-014-3611-z. Epub 2014 Mar 13.

PMID:
24623035
15.

Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.

Lim SH, Hong M, Ahn S, Choi YL, Kim KM, Oh D, Ahn YC, Jung SH, Ahn MJ, Park K, Zo JI, Shim YM, Sun JM.

Eur J Cancer. 2016 Jan;52:1-9. doi: 10.1016/j.ejca.2015.09.019. Epub 2015 Nov 26.

PMID:
26623522
16.

Neoadjuvant chemoradiotherapy and surgery compared with surgery alone in squamous cell carcinoma of the esophagus.

Andreollo NA, Tercioti Jr V, Lopes LR, de Souza Coelho-Neto J.

Arq Gastroenterol. 2013 Apr;50(2):101-6.

17.

The clinical significance of preoperative plasma fibrinogen level and platelet count in resectable esophageal squamous cell carcinoma.

Wang J, Liu H, Shao N, Tan B, Song Q, Jia Y, Cheng Y.

World J Surg Oncol. 2015 Apr 22;13:157. doi: 10.1186/s12957-015-0543-4.

18.

Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.

Valencia Julve J, Alonso Orduña V, Escó Barón R, López-Mata M, Méndez Villamón A.

Clin Transl Oncol. 2006 Jan;8(1):22-30.

PMID:
16632436
19.

Benefit of postoperative adjuvant chemoradiotherapy in locoregionally advanced esophageal carcinoma.

Rice TW, Adelstein DJ, Chidel MA, Rybicki LA, DeCamp MM, Murthy SC, Blackstone EH.

J Thorac Cardiovasc Surg. 2003 Nov;126(5):1590-6.

20.

Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.

Otowa Y, Nakamura T, Takiguchi G, Tomono A, Yamamoto M, Kanaji S, Imanishi T, Suzuki S, Tanaka K, Itoh T, Kakeji Y.

Dis Esophagus. 2016 Feb-Mar;29(2):146-51. doi: 10.1111/dote.12316. Epub 2014 Dec 17.

PMID:
25515972

Supplemental Content

Support Center